OBJECTIVES: We aimed to describe the levels of anxiety and depression in patients during the 3 month period following the end of chemotherapy treatment and to identify factors that predict psychological morbidity. METHOD: We performed a prospective study in women with ovarian cancer to determine the changes in psychological status in the 3 months following completion of chemotherapy. Sixty-three consecutive patients were assessed at the completion of chemotherapy (Time 1) and 57 at 3 months follow-up (Time 2). Relevant disease and patient characteristics were recorded and patients were assessed at Time 1 for anxiety, depression and their perception of emotional support, an index of their psychosocial environment. Anxiety and depression were re-assessed at Time 2. RESULTS: The results indicate significant initial psychological morbidity, with clinical caseness for anxiety (38%) and depression (33%) being common. Follow-up at Time 2 shows that patients undergo a significant reduction in cases (19%) and symptoms of depression but an increase in cases of anxiety (47%). The principal factors associated with symptoms of anxiety at Time 2 were poor perceived social support, increased intrusive thoughts and, to a lesser extent, younger age. Medical parameters, such as the stage of disease, response of the cancer to treatment, Ca125 (a tumour glycoprotein) and Karnofsky Performance status (a measure of how well the patients is) were not associated with worse psychological outcome. CONCLUSION: These data show for the first time that social support and intrusive thoughts, rather than physical parameters, are the principal determinants of psychological morbidity in patients with ovarian cancer.
OBJECTIVES: We aimed to describe the levels of anxiety and depression in patients during the 3 month period following the end of chemotherapy treatment and to identify factors that predict psychological morbidity. METHOD: We performed a prospective study in women with ovarian cancer to determine the changes in psychological status in the 3 months following completion of chemotherapy. Sixty-three consecutive patients were assessed at the completion of chemotherapy (Time 1) and 57 at 3 months follow-up (Time 2). Relevant disease and patient characteristics were recorded and patients were assessed at Time 1 for anxiety, depression and their perception of emotional support, an index of their psychosocial environment. Anxiety and depression were re-assessed at Time 2. RESULTS: The results indicate significant initial psychological morbidity, with clinical caseness for anxiety (38%) and depression (33%) being common. Follow-up at Time 2 shows that patients undergo a significant reduction in cases (19%) and symptoms of depression but an increase in cases of anxiety (47%). The principal factors associated with symptoms of anxiety at Time 2 were poor perceived social support, increased intrusive thoughts and, to a lesser extent, younger age. Medical parameters, such as the stage of disease, response of the cancer to treatment, Ca125 (a tumour glycoprotein) and Karnofsky Performance status (a measure of how well the patients is) were not associated with worse psychological outcome. CONCLUSION: These data show for the first time that social support and intrusive thoughts, rather than physical parameters, are the principal determinants of psychological morbidity in patients with ovarian cancer.
Authors: Ellen J Teng; Nancy J Petersen; Christine Hartman; Ellen Matthiesen; Michael Kallen; Karon F Cook; Marvella E Ford Journal: Int J Psychiatry Med Date: 2012 Impact factor: 1.210
Authors: Jody M Jackson; Sharon J Rolnick; Steve S Coughlin; Christine Neslund-Dudas; Mark C Hornbrook; Jeanne Darbinian; Donald J Bachman; Lisa J Herrinton Journal: Support Care Cancer Date: 2006-12-20 Impact factor: 3.603
Authors: Devesh Oberoi; Victoria M White; John F Seymour; H Miles Prince; Simon Harrison; Michael Jefford; Ingrid Winship; David Hill; Damien Bolton; Anne Kay; Jeremy Millar; Nicole Wong Doo; Graham Giles Journal: Support Care Cancer Date: 2017-06-30 Impact factor: 3.603
Authors: Spenser Hughes; Lisa M Jaremka; Catherine M Alfano; Ronald Glaser; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William B Farrar; Lisa D Yee; William E Carson; William B Malarkey; Janice K Kiecolt-Glaser Journal: Psychoneuroendocrinology Date: 2014-01-05 Impact factor: 4.905
Authors: William H Walker; O Hecmarie Meléndez-Fernández; Jordan L Pascoe; Ning Zhang; A Courtney DeVries Journal: Brain Behav Immun Date: 2020-07-29 Impact factor: 7.217
Authors: Susan K Lutgendorf; George M Slavich; Koenraad Degeest; Michael Goodheart; David Bender; Premal H Thaker; Frank Penedo; Bridget Zimmerman; Joseph Lucci; Luis Mendez; Katherine Collins; Anil K Sood Journal: Gynecol Oncol Date: 2013-10-03 Impact factor: 5.482
Authors: Jessica S Armer; Lauren Clevenger; Lauren Z Davis; Michaela Cuneo; Premal H Thaker; Michael J Goodheart; David P Bender; Laila Dahmoush; Anil K Sood; Steven W Cole; George M Slavich; Susan K Lutgendorf Journal: Cancer Date: 2018-06-15 Impact factor: 6.860